Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steve Hoerter
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Beta
- 0.10
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 62.74
Financials
Net Income
$-37.09MEBITDA
$-40.85MFree Cash Flow
$-23.52MEPS (diluted)
$-0.78Shares Outstanding (diluted)
47.70M+42.9%Operating Expenses
$40.93MCash & Debt
$418.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-86.97M | $-2.38 |
| 2024 | $0.00 | $-61.92M | $-1.85 |
| 2023 | $0.00 | $-32.56M | $-1.02 |
| 2022 | $0.00 | $-26.14M | $-0.82 |
Valuation
MBXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
118+46.88%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·12d ago·Positive
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy position MBX to challenge Yorvipath's standard-of-care status and potentially capture blockbuster revenues. MBX's early-stage obesity pipeline leverages monthly dosing and prodrug technology, targeting a massive market despite …
View source ↗ - Newsseekingalpha.com·19d ago·Positive
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
MBX Biosciences to Participate in Upcoming Investor Conferences CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will presen…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer CARMEL, Ind. and BURLINGTON, Mass.
View source ↗ - Newsglobenewswire.com·40d ago·Positive
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
View source ↗ - Newsaccessnewswire.com·54d ago·Negative
…ts Results for Q3 Fiscal 2026 Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing work to rebuild revenues back to profitability followi…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.80 per share
Typical surprise +17.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.78 vs $-0.63miss
- Thu, May 7$-0.51 vs $-0.62beat
- Thu, Mar 12$-0.49 vs $-0.64beat
- Thu, Nov 6$-0.63 vs $-0.73beat
- Thu, Aug 7$-0.58 vs $-0.77beat
- Mon, May 12$-0.71 vs $-0.81beat
Estimates and results for MBX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MBX officers and directors.
- Bought
- $73.7m
- Sold
- $2.7m
21 trades
5 trades
- Azoulay Salomonsold
- Azoulay Salomonsold
- Azoulay Salomonsold
- Azoulay Salomonsold
- Hawryluk P. Kentsold
- Hawryluk P. Kentbought
- Hawryluk P. Kentbought
- Hoerter Steven L.bought
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MBX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.